# Agenus Inc. (AGEN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $91M  
**Price:** $3.07 (-1.29%)

> Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies to treat cancer and infectious diseases. The company specializes in activating the body's immune system through advanced therapeutic approaches, operating both in the United States and internationally. Agenus develops a diverse pipeline of immunotherapy candidates, including its lead program combining botensilimab and balstilimab for cancer treatment, alongside other investigational therapies targeting various oncology and infectious disease indications. The company leverages proprietary technologies including its Retrocyte Display platform for antibody identification and development. Agenus has established strategic partnerships to advance its manufacturing capabilities and expand access to its therapeutic candidates. The company's approach emphasizes immunooncology and the development of novel treatment modalities to address significant unmet medical needs in cancer care and infectious disease management.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $114M | $113M | -$20M | — | — |
| 2024 | $103M | $103M | -$120M | — | — |
| 2023 | $156M | $153M | -$160M | — | — |
| 2022 | $98M | $87M | -$179M | — | — |
| 2021 | $296M | $292M | $26M | — | — |
| 2020 | $88M | $86M | -$117M | — | — |
| 2019 | $150M | — | -$70M | — | — |
| 2018 | $37M | — | -$124M | — | — |
| 2017 | $43M | — | -$104M | -$121M | — |
| 2016 | $23M | — | -$107M | -$127M | — |
| 2015 | $25M | — | -$81M | -$88M | — |
| 2014 | $7M | $7M | -$43M | -$42M | — |
| 2013 | $3M | $3M | -$25M | -$30M | — |
| 2012 | $16M | $15M | -$7M | -$11M | — |
| 2011 | $3M | $3M | -$19M | -$23M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $227M | — | -$271M | $3M | $45M |
| 2024 | $226M | — | -$326M | $40M | $33M |
| 2023 | $314M | — | -$160M | $76M | $13M |
| 2022 | $414M | — | -$61M | $179M | $13M |
| 2021 | $466M | — | $34M | $292M | $13M |
| 2020 | $215M | — | -$204M | $100M | $19M |
| 2019 | $155M | — | -$225M | $62M | $13M |
| 2018 | $136M | — | -$172M | $53M | $13M |
| 2017 | $138M | — | -$76M | $60M | $142M |
| 2016 | $157M | — | -$39M | $71M | $131M |
| 2015 | $242M | — | $71M | $137M | $114M |
| 2014 | $75M | — | $23M | $26M | $6M |
| 2013 | $35M | — | -$4M | $27M | $10M |
| 2012 | $29M | — | -$18M | $21M | — |
| 2011 | $20M | — | -$21M | $11M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$77M | $6,000 | -$77M |
| 2024 | -$158M | $576,000 | -$159M |
| 2023 | -$224M | $10M | -$234M |
| 2022 | -$175M | $53M | -$228M |
| 2021 | $10M | $34M | -$24M |
| 2020 | -$139M | $3M | -$143M |
| 2019 | -$19M | $5M | -$23M |
| 2018 | -$131M | $4M | -$135M |
| 2017 | -$94M | $3M | -$97M |
| 2016 | -$80M | $13M | -$92M |
| 2014 | -$38M | $3M | -$41M |
| 2013 | -$20M | $813,520 | -$20M |
| 2012 | $1M | $103,442 | $909,160 |
| 2011 | -$16M | $54,547 | -$16M |
| 2010 | -$15M | $130,437 | -$15M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AGEN)